Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium
about
Modelling and simulation as research tools in paediatric drug developmentAplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsA phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Current issues in oncology drug development, with a focus on Phase II trialsPhase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Innovations for phase I dose-finding designs in pediatric oncology clinical trials.Dose expansion cohorts in Phase I trials.Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia.Adaptive designs for dual-agent phase I dose-escalation studies.Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?Embracing model-based designs for dose-finding trials.A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.Incorporating adverse event relatedness into dose-finding clinical trial designs.A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.
P2860
Q27010366-75A19229-A349-4208-A90C-D5F4137D78AFQ28552571-78B87551-1C6C-4144-B025-87966579F266Q33418912-F34E4F6B-1FC8-49FF-8DB1-B88F835A9047Q33433456-CBE333B3-682A-41B9-AF45-B2A067AB496AQ33441292-3F3680DC-B23B-413F-A0C4-06E9223DD42CQ33465128-DFCEF56C-C7C9-41A9-B54B-AD152F99B35AQ33571622-29FEEABE-E945-4778-AEAD-6FDF10078488Q33772533-CEBB1C0B-93B1-437B-8FF0-DDFEC504FD04Q34193975-1D26F97E-69BD-491A-97F2-92405852891EQ35229738-6B0F9863-FC4D-4259-82E6-B2E02B452CD2Q36031619-CEF604A5-BCC9-4DDA-87B8-6BCBEB25A563Q36757843-0ACA385E-5E80-4C87-B1CB-EF9A51D28E98Q37158298-BBC1F3D9-3289-4B4F-B9F3-18E5C062678FQ37327945-83D804A1-5915-4695-B4BC-B8D4717252D5Q38090897-9EDFDE52-F256-446C-877A-6B4B0EAADC4AQ38543293-872ADEEF-FC07-4579-B957-3D314B35264BQ38700689-64B63252-F3D2-4D8B-B5F0-2E45D1052809Q40313777-4A560DAB-961B-497A-BAFF-E5869A2BF23DQ43088013-94031A8B-C440-4A70-878D-6353F0E2F594Q43681160-FD425C77-9328-4DBE-AB99-B263C7E8BFD1Q46036046-E1CF885E-5A6F-4B04-85D4-0411E5E8D257Q52692689-6CE1A2F5-5097-4CD7-B477-AD8D66E37A7C
P2860
Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Continual reassessment method ...... diatric Brain Tumor Consortium
@ast
Continual reassessment method ...... diatric Brain Tumor Consortium
@en
Continual reassessment method ...... diatric Brain Tumor Consortium
@nl
type
label
Continual reassessment method ...... diatric Brain Tumor Consortium
@ast
Continual reassessment method ...... diatric Brain Tumor Consortium
@en
Continual reassessment method ...... diatric Brain Tumor Consortium
@nl
prefLabel
Continual reassessment method ...... diatric Brain Tumor Consortium
@ast
Continual reassessment method ...... diatric Brain Tumor Consortium
@en
Continual reassessment method ...... diatric Brain Tumor Consortium
@nl
P2860
P1476
Continual reassessment method ...... diatric Brain Tumor Consortium
@en
P2093
James M Boyett
P2860
P304
P356
10.1080/10543400902800486
P50
P577
2009-01-01T00:00:00Z